Ipilimumab/nivolumab/pembrolizumabLack of efficacy: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2030卷 / 1期

关键词：

D O I：

10.1007/s40278-024-69043-4

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：242 / 242

相关论文

共 50 条

[41] PembrolizumabLack of efficacy: case report
Reactions Weekly, 2024, 2035 (1) : 416 - 416
[42] PembrolizumabLack of efficacy: case report
Reactions Weekly, 2022, 1919 (1) : 495 - 495
[43] PembrolizumabLack of efficacy: case report
Reactions Weekly, 2023, 1946 (1) : 457 - 457
[44] PembrolizumabLack of efficacy: case report
Reactions Weekly, 2021, 1844 (1) : 367 - 367
[45] PembrolizumabLack of efficacy: case report
Reactions Weekly, 2022, 1910 (1) : 393 - 393
[46] PembrolizumabLack of efficacy: case report
Reactions Weekly, 2023, 1978 (1) : 314 - 314
[47] Ipilimumab/nivolumab/topotecanLack of efficacy and reactivation of tuberculosis: case report
Reactions Weekly, 2021, 1852 (1) : 249 - 249
[48] Ipilimumab/nivolumab/pembrolizumabVarious toxicities and lack of efficacy: case report
Reactions Weekly, 2022, 1917 (1) : 328 - 328
[49] PembrolizumabLack of efficacy: case report
Reactions Weekly, 2024, 2030 (1) : 420 - 420
[50] PembrolizumabLack of efficacy: case report
Reactions Weekly, 2022, 1909 (1) : 456 - 456

← 1 2 3 4 5 →